mTCTScan

mTCTScan analyzes mutation-driven cancer drug sensitivity by integrating individual genomic profiles with chemical screening data from human cancer cell lines to prioritize mutation–drug associations.

Key Features:

• Systematic Analysis of Mutations: Integrates knowledge of mutation–drug sensitivity associations derived from large-scale chemical screening data using human cancer cell lines.
• Evidence-Based Scoring Scheme: Employs an evidence-based scoring scheme to prioritize mutations based on their associations with specific cancer drugs and preclinical compounds.
• Contextual Genomic Profile Analysis: Considers the entire genomic profile to generate context-specific sensitivity classifications for individual tumors.
• Comprehensive Filtering and Annotations: Provides filtering functions and cancer-related annotations to support interpretation of mutation effects and therapeutic associations.

Scientific Applications:

• Interrogation of Mutation-Dependent Drug Response Mechanisms: Enables exploration of how specific mutations alter drug efficacy using integrated chemical screening and genomic data.
• Personalized Treatment Strategies: Supports selection of candidate therapeutic agents tailored to individual tumor genomic profiles.

Methodology:

Integrating large-scale chemical screening data from human cancer cell lines; utilizing an evidence-based scoring scheme to prioritize mutations according to their relevance to drug sensitivity; analyzing genomic profiles comprehensively to identify context-specific drug sensitivities.